Indications for Imatinib Mesylate Therapy and Clinical Management

Indications for Imatinib Mesylate Therapy and Clinical Management François Guilhot Oncologist 2004; 9: 271-281 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in acute and chronic leukemias and multiple myeloma and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the mechanism of action (i.e., the molecular targets) of the anticancer drug imatinib mesylate. Explain how inhibition of these targets confers clinical benefits in specific human cancers. List the most common clinical side effects of imatinib treatment. Manage the side effects of imatinib treatment so as to allow optimal patient management. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: May 28, 2004 Most Recent Review: May 28, 2004* Most Recent Update: May 28, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.